Learn Before
Outcomes among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion
A single-center, uncontrolled study of 100 severe COVID-19 patients at Spedali Civili di Brescia, Italy, treated with tocilizumab (TCZ) and followed for 10 days. Reports patient characteristics, laboratory findings, and methods, then clinical outcomes at two checkpoints: 24–72 h after TCZ infusion (58% improved, 37% stabilized, 5% worsened) and 10 days after infusion (77% improved or stabilized, 23% worsened, 20% died). The discussion notes these findings are preliminary since the study was neither randomized nor controlled.
0
1
Contributors are:
Who are from:
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Outcomes among 100 severe COVID-19 patients in Brescia, Italy during 10-day follow-up after Tocilizumab (TCZ) infusion
Figure illustrating how Tocilizumab calms the inflammatory storm by blocking IL-6 receptors
Severe COVID-19 cases and the impact of tocilizumab
Toxicities of TCZ
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
Case Report of Tocilizumab for COVID-19 Pneumonia in a Non Small Cell Lung Cancer Patient Treated with Chemo-Immunotherapy
Treatment with Tocilizumab or Corticosteroids for COVID-19 Patients with Hyperinflammatory State
Learn After
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Outcomes among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Patient characteristics among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Laboratory findings among 100 severe COVID-19 patients in Brescia, Italy 10 days after Tocilizumab (TCZ) infusion
Methods for tracking outcomes among 100 severe COVID-19 patients in Brescia, Italy 24–72 h after Tocilizumab (TCZ) infusion
Discussion from "Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy"